Fresh analysis suggests that individuals who stop using popular slimming jabs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end traditional diet and exercise regimens.
Published data in a leading health publication shows that while obese individuals can lose substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these medications need to be informed of the potential of fast rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb.
That rate of regain suggests a return to original weight in about a year and a half.
Weighing Approaches
The study, which reviewed 37 of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
Researchers note that people who shed pounds through diet and exercise usually have a slower creep back—around 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Doctors believe the way of the drugs is key to understanding the accelerated regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Condition?
Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the likelihood of relapse, the treatment is often long-term.
This view is supported by pharmaceutical companies, who note that the results "underscore the long-term character of obesity," akin to managing diseases like hypertension.
User Experiences
People who have stopped the medication describe a sudden return of hunger.
"I experienced a switch that goes on and you become ravenous," said an individual.
This difficulty is worsened if patients have not adopted lasting lifestyle or habit changes during treatment.
Widespread Use
Figures suggest that millions of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Use is more common among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone solution and maintained weight loss relies on combined behavioural support.
